University of Pittsburgh researchers have developed a novel HSV mutant virus, designated d109, which lacks several immediate-early proteins (ICP4, ICP0, ICP27, ICP22, and ICP47). This mutant virus demonstrates the ability to persist and express the herpes simplex virus (HSV) genome in the absence of these proteins, making it a promising tool for gene therapy and vaccine development. The d109 virus offers a unique approach to studying HSV biology and developing therapeutic strategies.
Description
The HSV mutant virus d109 is engineered to lack five immediate-early proteins, which are crucial for the virus's replication and pathogenesis. This modification allows the virus to persist in host cells without causing disease, providing a safe and effective vector for gene delivery. The d109 virus has been described in the Journal of Virology (Vol. 72, No. 4, April 1998, pp. 3307-3320) and is covered by patents related to herpes simplex virus vectors and strains (US Patents 6,261,552 and 7,078,029).
Applications
- Gene therapy for genetic disorders
- Vaccine development for HSV and other pathogens
- Research tool for studying HSV biology and pathogenesis
- Development of novel antiviral therapies
Advantages
The HSV mutant virus d109 offers several advantages, including the ability to persist in host cells without causing disease, making it a safe vector for gene delivery. Its lack of immediate-early proteins reduces the risk of reactivation and pathogenesis, enhancing its safety profile. The virus's ability to express the HSV genome in the absence of these proteins provides a unique tool for studying HSV biology and developing new therapeutic strategies.
Invention Readiness
The technology is currently at the in vivo data stage. Initial experiments have demonstrated that the d109 virus can persist in host cells and express the HSV genome without the immediate-early proteins, as described in the Journal of Virology. These studies showed that the virus could maintain its genome and express viral genes in the absence of ICP4, ICP0, ICP27, ICP22, and ICP47, indicating its potential as a gene delivery vector. Further research is ongoing to optimize the virus for gene therapy and vaccine development applications. Preclinical models have shown promising results, and additional studies are planned to evaluate the efficacy and safety of the d109 virus in clinical settings.
IP Status
Research Tool
